NRAS, RUNX1 POLYMORPHISM AND CHROMOSOME 5 DELETION [DEL(5q)] AS MYELODYSPLASTIC SYNDROME RELATED ACUTE MYELOID LEUKEMIA PREDICTOR IN SURABAYA
INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY · 13.03.2026 · 32 (2) · 198-204
DOI: 10.24293/ijcpml.v32i2.2828 ↗Kurz gefasst
Fachartikel in der Zeitschrift INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY, online erschienen am 13.03.2026. Verfasst von Mulya Dinata und 9 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-SA 4.0).
Abstract (Originalsprache)
Myelodysplastic syndrome (MDS) is a well-organized hematopoiesis (Apoptosis) that becomes dysplastic and ineffective (Anti-Apoptosis). It is characterized by a slight increase in the number of immature blood cells (Blasts) in bone marrow, which can develop into acute myeloid leukemia (AML; MDS-related AML). In this study, Researchers sought to determine whether abnormalities in NRAS, RUNX1, and chromosome 5 deletion (del[5q]) can be used as predictors of MDS-related AML. This study employed an analytical cross-sectional design involving a total of 36 samples, consisting of 31 confirmed AML cases and 5 clinically diagnosed MDS cases. The occurrence of NRAS, RUNX1 mutations, and deletion of chromosome 5 deletion (del[5q]) was examined using polymerase chain reaction (PCR) and chromogenic in situ hybridization (CISH). Our analysis demonstrates that NRAS and RUNX1 mutations, alongside chromosome 5q deletion (del[5q]), are significantly associated with the progression of MDS-related AML. Statistical evaluation via ROC curve showed an AUC of 0.765 (95% CI, p=0.036), demonstrating the model’s significant performance in predicting disease progression. Above or below the cut-off value (0.7825584010 ) indicates strong or weak predictions of MDS-related AML based on the ROC curve. Mutation of RUNX1 coefficient B-1.694 and exponent B 0.184 decreased the progression to MDS-related AML, while NRAS mutation coefficient 2.446 and exponent B 11.53 increased the progression of MDS-related AML. Normal cytogenetics of Chromosome 5, RUNX1 mutation inhibits progression, while NRAS mutation increases progression of MDS-related AML. NRAS and RUNX1 mutations, as well as Chromosome 5 deletion (del[5q]) can be strong predictors of progression to MDS-related AML in Surabaya.
Zitieren
APA
Dinata, M., Bintoro, D. D. S. U. Y., Sp.PD, K-HOM, Widjajanto, P. D. D. E., MS., (K), S. P., Purnomo, D. W., dr., & M.S. (2026). NRAS, RUNX1 POLYMORPHISM AND CHROMOSOME 5 DELETION [DEL(5q)] AS MYELODYSPLASTIC SYNDROME RELATED ACUTE MYELOID LEUKEMIA PREDICTOR IN SURABAYA. INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY, 32(2), 198-204. https://doi.org/10.24293/ijcpml.v32i2.2828
Vancouver
Dinata M, Bintoro DDSUY, Sp.PD, K-HOM, Widjajanto PDDE, MS., et al. NRAS, RUNX1 POLYMORPHISM AND CHROMOSOME 5 DELETION [DEL(5q)] AS MYELODYSPLASTIC SYNDROME RELATED ACUTE MYELOID LEUKEMIA PREDICTOR IN SURABAYA. INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY. 2026;32(2):198-204. doi:10.24293/ijcpml.v32i2.2828
BibTeX
@article{Dinata2026,
author = {Dinata, Mulya and Bintoro, Dr. dr. Siprianus Ugroseno Yudho and Sp.PD and K-HOM and Widjajanto, Prof. Dr. dr. Edi and MS. and (K), Sp PK and Purnomo, Dr. Windhu and dr. and M.S.},
title = {NRAS, RUNX1 POLYMORPHISM AND CHROMOSOME 5 DELETION [DEL(5q)] AS MYELODYSPLASTIC SYNDROME RELATED ACUTE MYELOID LEUKEMIA PREDICTOR IN SURABAYA},
journal = {INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY},
year = {2026},
volume = {32},
number = {2},
pages = {198--204},
doi = {10.24293/ijcpml.v32i2.2828}
}
EUVIMED